Literature DB >> 28167847

Decreased Expression of Hsa_circ_00001649 in Gastric Cancer and Its Clinical Significance.

Wen-Han Li1, Yong-Chun Song1, Hao Zhang1, Zhang-Jian Zhou1, Xin Xie1, Qing-Nuo Zeng1, Kun Guo2, Ting Wang3, Peng Xia1, Dong-Min Chang1.   

Abstract

Background. It has been reported that circRNAs are differentially expressed in a wide range of cancers and could be used as a new biomarker for diagnosis. However, the correlation between circRNAs and gastric cancer (GC) it is still unclear. Materials and Methods. In this study, by using real-time quantitative reverse transcription-polymerase chain reactions (qRT-PCRs), we detected the expression level of hsa_circ_0001649 in tissue and serum samples from GC patients. Results. We found that hsa_circ_0001649 expression was significantly downregulated in GC tissue compared with their paired paracancerous histological normal tissues (PCHNTs) (P < 0.01). We next analyzed the expression level of hsa_circ_0001649 in serum samples between preoperative and postoperative GC patients. We found that its level in serum was significantly upregulated after surgery (P < 0.01). The area under the receiver operating characteristic (ROC) curve was 0.834. Moreover, the expression level of hsa_circ_0001649 was significantly correlated with pathological differentiation (P = 0.039). Conclusion. Our test suggested that hsa_circ_0001649 was significantly downregulated in GC and may become a novel potential biomarker in the diagnosis of GC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28167847      PMCID: PMC5266807          DOI: 10.1155/2017/4587698

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


1. Introduction

Although the incidence of gastric cancer (GC) has declined in recent years, it is still one of the common malignancies worldwide, accounting for 841,000 deaths in 2013 [1]. Patients with advanced gastric cancer are often associated with extremely poor prognosis [2]. Therefore, developing a diagnosis panel in GC may help discovering the susceptible population earlier, which could increase the patients' probability to achieve complete cure. Circular RNAs (circRNAs) are a large class of endogenous noncoding RNAs that attract increasing attention in the field of RNA recently. Compared with linear RNAs that are terminated with 5′caps and 3′tails, circRNAs exhibited a remarkable characteristic of undergoing “backsplicing” without a free 3′ or 5′ end [3-5]. Subsequent reports revealed that circRNAs participate in a wide range of biological processes, including competition with endogenous RNAs for binding to miRNAs, or regulate alternative splicing [4, 6]. It was also demonstrated that circRNAs are involved in the initiation and progression of several types of cancer [7-9]. Moreover, compared with mRNAs, circRNAs are resistant to exonucleolytic activities and are stable in extracellular space. Memczak et al. [10] found that circRNAs are readily detectable in clinical whole blood specimen. The above evidence led us to wonder whether circRNAs serve as a new biomarker for tumor diagnosis, prognosis, and therapeutic response prediction [11, 12]. By analyzing bioinformatics information in two circRNA databases (CircBase and circ2Traits), we predicted that hsa_circ_0001649, which is located at chr6:146209155-146216113, has a strong association with GC (P < 0.01). Its associated gene symbol is a tumor suppressor gene named SHPRH. Depletion of SHPRH could be observed in a variety of cancer types, such as prostate cancer, ovarian cancer, and liver cancer [13, 14]. In the present study, we set out to detect hsa_circ_0001649 in tissue and serum samples from patients harboring gastric tumor at various stages. Besides, we also analyzed the relationships between hsa_circ_0001649 expression level and clinicopathological findings to assess the diagnostic value of this marker for the early detection of primary GC.

2. Materials and Methods

2.1. Patients and Clinical Specimens

In order to reduce bias, we designed this experiment as a blinded assay. All samples' collection and preservation were done by a person who did not participate in the follow-up studies. Patients with primary GC who participated in this study were recruited consecutively. The study material of this study included 76 tumor tissue samples and their paired paracancerous histological normal tissues (PCHNTs) which were obtained during curative surgery. In the meantime, 20 patients' whole blood samples were collected preoperatively and postoperatively (more than 20 days after surgery). None of the experimental subjects had received prior gastric resection or preoperative chemotherapy/radiation therapy. All samples were immediately frozen and stored at −80°C until total RNA was extracted. In order to reduce bias, samples were randomly coded before processing. All patients voluntarily joined this study with written informed consent to have their biologic specimens analyzed. This study was announced by the Ethical Committee of the First Affiliated Hospital of Xi'an Jiaotong University.

2.2. Cell Culture

Immortalized human gastric cancer cell lines, SGC-7901, were used in this study. We purchased the cell line from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cells were routinely cultured in RPMI-1640 medium (Gibco) supplemented with 10% fetal bovine serum (Hyclone) at 37°C in a humidified atmosphere containing 5% CO2.

2.3. Total RNA Extraction

TRIzol reagent (Ambion, life technologies, USA) was used to extract RNA from cells and tissues according to the manufacturer's instructions, and total RNA in plasma was extracted using TRIzol LS Reagent (Invitrogen), following the manufacturer's instructions. Then, concentration of RNA was measured by ultraviolet spectrophotography.

2.4. Reverse Transcription

cDNA was synthesized by reverse transcription (RT) using a Primescript RT reagent kit with random primers according to manufacturer-provided protocols (TaKaRa).

2.5. Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)

The qRT-PCR was achieved using SYBR Premix Ex Taq™ II (Tli RNaseH Plus) (TaKaRa) on CFX96 Real-Time PCR Detection System (Bio-Rad, California, USA) following the manufacturer's instructions. Divergent primers, rather than convergent primers, were synthesized by Sangon Biotech (Shanghai, China). We use GAPDH as an internal control. The primers used for qRT-PCR are summarized in Table 1. All reactions were performed in triplicate.
Table 1

qRT-PCR primer sequences.

Primer setForward primerReverse primer
Hsa_circ_0001649AATGCTGAAAACTGCTGAGAGAATTGAGAAAACGAGTGCTTTGG
GAPDHTCGACAGTCAGCCGCATCTTCTTTACCAAATCCGTTGACTCCGACCTT

2.6. CEA, CA19-9, and CA-724 Measurements

Normal levels of CEA, CA19-9, and CA-724 were defined as <3.4 ng/mL, <39 U/mL, and <9.8 U/mL, respectively. The tests were done independently at the clinical laboratory in the First Affiliated Hospital of Xi'an Jiaotong University College of Medicine.

2.7. Statistical Analysis

Statistical analysis was performed with the SPSS 13.0 software (SPSS, Chicago, IL, USA) and GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). The qPCR results were analyzed using 2−ΔΔCt method. The correlation of hsa_circ_0001649 expression level between GC and their matched gastric nontumorous tissues or serum samples were calculated using paired t-test. The correlations between hsa_circ_0001649 levels and clinicopathological factors were further analyzed by one-way analysis of variance (ANOVA). Receiver operating characteristic (ROC) curve was constructed using SPSS 13.0 to evaluate the diagnostic values. P values < 0.05 (two-sided) were considered statistically significant.

3. Results

3.1. Patient Characteristics

In order to explore the expression level of hsa_circ_0001649 in GC, 76 paired GC and PCHNTs tissue samples (including 61 males and 15 females) were enrolled in this study. The mean age of GC patients was 57.9 ± 11.6. Besides, we analyzed hsa_circ_0001649 expression level in 20 paired preoperative and postoperative serum samples.

3.2. Existence of Hsa_circ_0001649 in Gastric Cancer Cells

We used divergent primers to amplify hsa_circ_0001649 in SGC-7901 cell line. The amplified product yielded a single peak in a melting curve analysis. The qRT-PCR products were then sequenced and the result showed that the sequence was completely consistent with that from CircBase (Figure 1). So we concluded that hsa_circ_0001649 existed in gastric cancer and could be amplified by qRT-PCR.
Figure 1

Sanger sequencing result of hsa_circ_0001649 showed the backsplice junction.

3.3. Hsa_circ_0001649 Expression Was Downregulated in Gastric Cancer Tissues

We first examined the expression level of hsa_circ_0001649 in 76 tissue samples of GC patients and PCHNTs by qRT-PCR, when using GAPDH as the internal standard. Our results showed that hsa_circ_0001649 expression in GC tissue was significantly lower than those in corresponding nontumorous tissues (n = 76, P < 0.01) (Figure 2).
Figure 2

The expression levels of hsa_circ_0001649 in GC tissue samples and their paired PCHNTs. The picture showed that hsa_circ_0001649 expression in GC tissue was significantly lower than those in corresponding nontumorous tissues (n = 76, P < 0.01).

3.4. Hsa_circ_0001649 Expression Was Upregulated in Gastric Cancer Serum Samples after Surgery

To further investigate whether hsa_circ_0001649 could be used as a biomarker for GC, we detected its expression level in serum samples. Our data suggested that comparing with preoperatively collected samples, hsa_circ_0001649 expression level was significantly upregulated in those serum samples collected postoperatively (P < 0.01) (Figure 3). The above evidence suggested that hsa_circ_0001649 was downregulated in either GC tissue samples or GC serum samples compared to control groups (all P values < 0.01)and, therefore, may be considered as a panel for the early detection of GC.
Figure 3

The expression levels of hsa_circ_0001649 in serum samples was significantly upregulated in those serum samples collected postoperatively (n = 20, P < 0.01).

3.5. Potential Diagnostic Values of Hsa_circ_0001649 in Gastric Cancer

Our results revealed differential expression of hsa_circ_0001649 between gastric cancer tissues and nontumorous tissues as well as in plasma samples. We next explored the correlation between clinicopathological data and the expression level of hsa_circ_0001649; the results were shown in Table 2. We found that hsa_circ_0001649 expression level was associated with pathological differentiation (P = 0.039). On the contrary, no correlation was found of hsa_circ_0001649 expression level with other clinicopathological factors, including age, gender, TNM stage, lymphatic metastasis, CEA, CA19-9, and CA-724 levels. Then we built a ROC curve to estimate the diagnostic values of this circRNA in gastric cancer. The sensitivity and specificity were 0.711 and 0.816, respectively. The cutoff value was 0.22692250 and the area under the curve was 0.834 (Figure 4).
Table 2

Correlation between hsa_circ_0001649 expression and clinicopathological parameters in GC patients.

ParametersNumber of casesMean ± SD P value
Age
 <60420.14 ± 0.130.549a
 ≥60340.16 ± 0.12
Gender
 Male610.15 ± 0.120.834a
 Female150.15 ± 0.16
Pathological differentiation
 Well + moderate310.18 ± 0.140.039a
 Poor + undifferentiation450.12 ± 0.10
Depth of tumor invasion
 Tis, T1a, T1b80.15 ± 0.160.366a
 T2100.08 ± 0.06
 T3100.16 ± 0.17
 T4a, T4b480.16 ± 0.17
Lymph node metastasis
 N0280.12 ± 0.110.389a
 N1230.18 ± 0.13
 N290.19 ± 01.8
 N3a, N3b160.14 ± 0.09
TNM Stage
 I, II390.14 ± 0.130.386a
 III, IV370.16 ± 0.12
CEA
 Positive170.15 ± 0.110.914a
 Negative590.15 ± 0.13
CA19-9
 Positive100.15 ± 0.120.958a
 Negative660.15 ± 0.13
CA-724
 Positive80.08 ± 0.050.118a
 Negative680.16 ± 0.13

aUsing chi-square for this statistic.

Figure 4

ROC curve of Hsa_circ_0001649. Area under the curve was 0.834. The sensitivity and specificity were 0.711 and 0.816, respectively.

4. Discussion

circRNAs are novel members of noncoding RNA family that are formed by the noncanonical splicing of linear pre-mRNAs. Although circRNAs have been known to exist for 20 years [15-17], the characteristics and the critical role of circRNA in co-/posttranscriptional regulation have only been revealed recently [4]. Studies have shown that circRNAs regulate gene expression mainly by acting as microRNAs (miRNAs) sponge [4, 18, 19], regulator of translation [20], binding protein [5], and RNA transport [21]. The most well known circular RNA sponges so far are ciRS-7 and sex-determining region Y (SRY), targeting microRNA-7 (miR-7) and microRNA-138 (miR-138), respectively [4, 6]. Moreover, misregulation of circRNAs leads to abnormal cellular functions and growth defects. Differentially expressed circRNAs in a wide range of cancers may play an important role in cancer initiation and progression [12]. For example, Huang et al. [7] have shown that cir-ITCH expression is typically downregulated in CRC in comparison with paired adjacent tissue. And Li et al. [8] have revealed that hsa_circ_002059 is downregulated in GC cancer. According to previous publications, circRNAs are more stable than linear mRNA in RNA exonucleases. The increase or decrease in circRNAs expression levels in tumors compared with normal tissues may serve as a useful biomarker in tumor diagnosis and prognosis. In this study, based on previous research and two circRNA databases (circ2traits and CircBase), we found that the expression level of hsa_circ_0001649 is significantly downregulated in GC tissues when compared to the PCHNTs (P < 0.01). The analysis between circRNA expression level and clinicopathological data demonstrated that the expression level of hsa_circ_0001649 was more significantly decreased in poor and undifferentiated tumors than in well differentiated ones (P = 0.039). This phenomenon indicates that hsa_circ_0001649 level may have a negative correlation with GC pathological differentiation. However, detailed molecular mechanisms of hsa_circ_0001649 involved in GC progression are still mysterious. We next estimated the diagnostic value of hsa_circ_0001649 in GC. A comparatively satisfactory result was obtained by using ROC curve analysis (the sensitivity and specificity were 0.711 and 0.816, respectively; the area under the curve was 0.834). Our preliminary results indicate that hsa_circ_0001649 expression level was downregulated in GC tissue sample compared with normal ones and has the potential to be used as a novel biomarker for GC with high degrees of accuracy, specificity, and sensitivity. Recently, some articles reported that changes of circRNAs expression level in fluids paralleled other somatic tissues and are thought to be connected with certain cancers. Li et al. [8] examined the levels of hsa_circ_002059 in plasma samples between preoperative and postoperative gastric cancer patients. They found that circulating hsa_circ_002059 expression level was significantly upregulated after surgery. Memczak et al. [10] sequenced circRNAs in human peripheral whole blood and testified the reproducibility of the detection method of thousands of circRNAs in blood samples. They concluded that circRNAs could be used as biomarker molecules in standard clinical blood samples. Li et al. [11] examined serum exosome from patients with CRC and normal serum and found 67 circRNAs were missing and 257 new circRNA species in CRC. Enlightened by the above studies, we tested hsa_circ_0001649 expression level in 20 paired GC serum samples. By analyzing experimental data, we found that hsa_circ_0001649 expression level was significantly upregulated in GC serum samples after surgery (P < 0.01). However, our study just validated the dysregulation of hsa_circ_0001649 in GC tissue and serum samples. Further experiments still need to be done to elucidate the role of hsa_circ_0001649 in the generation and progression of GC. In summary, by comparing the expression level of hsa_circ_0001649 in tissue and serum samples, we found that detecting hsa_circ_0001649 between GC and normal ones has a relatively high sensitivity and specificity and, therefore, may be used as a biomarker for noninvasive screening of GC.
  21 in total

1.  Cloning and characterization of a novel gene, SHPRH, encoding a conserved putative protein with SNF2/helicase and PHD-finger domains from the 6q24 region.

Authors:  Raman Sood; Izabela Makalowska; Michal Galdzicki; Ping Hu; Erica Eddings; Christiane M Robbins; Tracy Moses; Jin Namkoong; Suzie Chen; Jeffrey M Trent
Journal:  Genomics       Date:  2003-08       Impact factor: 5.736

Review 2.  Circular RNA and miR-7 in cancer.

Authors:  Thomas B Hansen; Jørgen Kjems; Christian K Damgaard
Journal:  Cancer Res       Date:  2013-09-06       Impact factor: 12.701

3.  Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis.

Authors:  Yan Li; Qiupeng Zheng; Chunyang Bao; Shuyi Li; Weijie Guo; Jiang Zhao; Di Chen; Jianren Gu; Xianghuo He; Shenglin Huang
Journal:  Cell Res       Date:  2015-07-03       Impact factor: 25.617

4.  The Global Burden of Cancer 2013.

Authors:  Christina Fitzmaurice; Daniel Dicker; Amanda Pain; Hannah Hamavid; Maziar Moradi-Lakeh; Michael F MacIntyre; Christine Allen; Gillian Hansen; Rachel Woodbrook; Charles Wolfe; Randah R Hamadeh; Ami Moore; Andrea Werdecker; Bradford D Gessner; Braden Te Ao; Brian McMahon; Chante Karimkhani; Chuanhua Yu; Graham S Cooke; David C Schwebel; David O Carpenter; David M Pereira; Denis Nash; Dhruv S Kazi; Diego De Leo; Dietrich Plass; Kingsley N Ukwaja; George D Thurston; Kim Yun Jin; Edgar P Simard; Edward Mills; Eun-Kee Park; Ferrán Catalá-López; Gabrielle deVeber; Carolyn Gotay; Gulfaraz Khan; H Dean Hosgood; Itamar S Santos; Janet L Leasher; Jasvinder Singh; James Leigh; Jost B Jonas; Jost Jonas; Juan Sanabria; Justin Beardsley; Kathryn H Jacobsen; Ken Takahashi; Richard C Franklin; Luca Ronfani; Marcella Montico; Luigi Naldi; Marcello Tonelli; Johanna Geleijnse; Max Petzold; Mark G Shrime; Mustafa Younis; Naohiro Yonemoto; Nicholas Breitborde; Paul Yip; Farshad Pourmalek; Paulo A Lotufo; Alireza Esteghamati; Graeme J Hankey; Raghib Ali; Raimundas Lunevicius; Reza Malekzadeh; Robert Dellavalle; Robert Weintraub; Robyn Lucas; Roderick Hay; David Rojas-Rueda; Ronny Westerman; Sadaf G Sepanlou; Sandra Nolte; Scott Patten; Scott Weichenthal; Semaw Ferede Abera; Seyed-Mohammad Fereshtehnejad; Ivy Shiue; Tim Driscoll; Tommi Vasankari; Ubai Alsharif; Vafa Rahimi-Movaghar; Vasiliy V Vlassov; W S Marcenes; Wubegzier Mekonnen; Yohannes Adama Melaku; Yuichiro Yano; Al Artaman; Ismael Campos; Jennifer MacLachlan; Ulrich Mueller; Daniel Kim; Matias Trillini; Babak Eshrati; Hywel C Williams; Kenji Shibuya; Rakhi Dandona; Kinnari Murthy; Benjamin Cowie; Azmeraw T Amare; Carl Abelardo Antonio; Carlos Castañeda-Orjuela; Coen H van Gool; Francesco Violante; In-Hwan Oh; Kedede Deribe; Kjetil Soreide; Luke Knibbs; Maia Kereselidze; Mark Green; Rosario Cardenas; Nobhojit Roy; Taavi Tillmann; Taavi Tillman; Yongmei Li; Hans Krueger; Lorenzo Monasta; Subhojit Dey; Sara Sheikhbahaei; Nima Hafezi-Nejad; G Anil Kumar; Chandrashekhar T Sreeramareddy; Lalit Dandona; Haidong Wang; Stein Emil Vollset; Ali Mokdad; Joshua A Salomon; Rafael Lozano; Theo Vos; Mohammad Forouzanfar; Alan Lopez; Christopher Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

Review 5.  Circular RNAs: a new frontier in the study of human diseases.

Authors:  Yonghua Chen; Cheng Li; Chunlu Tan; Xubao Liu
Journal:  J Med Genet       Date:  2016-03-03       Impact factor: 6.318

6.  Using circular RNA as a novel type of biomarker in the screening of gastric cancer.

Authors:  Peifei Li; Shengcan Chen; Huilin Chen; Xiaoyan Mo; Tianwen Li; Yongfu Shao; Bingxiu Xiao; Junming Guo
Journal:  Clin Chim Acta       Date:  2015-02-14       Impact factor: 3.786

7.  Circular RNAs are a large class of animal RNAs with regulatory potency.

Authors:  Sebastian Memczak; Marvin Jens; Antigoni Elefsinioti; Francesca Torti; Janna Krueger; Agnieszka Rybak; Luisa Maier; Sebastian D Mackowiak; Lea H Gregersen; Mathias Munschauer; Alexander Loewer; Ulrike Ziebold; Markus Landthaler; Christine Kocks; Ferdinand le Noble; Nikolaus Rajewsky
Journal:  Nature       Date:  2013-02-27       Impact factor: 49.962

8.  Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma.

Authors:  Meilin Qin; Gang Liu; Xisong Huo; Xuemei Tao; Xiaomeng Sun; Zhouhong Ge; Juan Yang; Jia Fan; Lei Liu; Wenxin Qin
Journal:  Cancer Biomark       Date:  2016       Impact factor: 4.388

9.  Circular intronic long noncoding RNAs.

Authors:  Yang Zhang; Xiao-Ou Zhang; Tian Chen; Jian-Feng Xiang; Qing-Fei Yin; Yu-Hang Xing; Shanshan Zhu; Li Yang; Ling-Ling Chen
Journal:  Mol Cell       Date:  2013-09-12       Impact factor: 17.970

10.  cir-ITCH plays an inhibitory role in colorectal cancer by regulating the Wnt/β-catenin pathway.

Authors:  Guanli Huang; Hua Zhu; Yixiong Shi; Wenzhi Wu; Huajie Cai; Xiangjian Chen
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

View more
  41 in total

1.  Analysis of co-expression networks for circular RNAs and mRNAs reveals that circular RNAs hsa_circ_0047905, hsa_circ_0138960 and has-circRNA7690-15 are candidate oncogenes in gastric cancer.

Authors:  Zhiyong Lai; Yang Yang; Yichao Yan; Tao Li; Yansen Li; Zhu Wang; Zhanlong Shen; Yingjiang Ye; Kewei Jiang; Shan Wang
Journal:  Cell Cycle       Date:  2017-11-09       Impact factor: 4.534

Review 2.  The emerging role of circular RNAs in gastric cancer.

Authors:  Peina Shi; Jiangnan Wan; Haojun Song; Xiaoyun Ding
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

3.  CircRNA hsa_circ_100395 regulates miR-1228/TCF21 pathway to inhibit lung cancer progression.

Authors:  Daishi Chen; Wei Ma; Zhaoyang Ke; Fei Xie
Journal:  Cell Cycle       Date:  2018-09-13       Impact factor: 4.534

4.  Genome-wide CRISPR knockout screening identified G protein pathway suppressor 2 as a novel tumor suppressor for uveal melanoma metastasis.

Authors:  Shuangshuang Shi; Haojie Chen; Hanqing Wang; JianFeng Wan; Yi Shi; Jia Li; Shuo Wang; Jie Shi; Jianying Lv; Tong Wu; Longlong Wang; Fengyuan Sun
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-08       Impact factor: 4.322

Review 5.  The progress of circular RNAs in various tumors.

Authors:  Dandan Wang; Sujin Yang; Hui Wang; Jinyan Wang; Qian Zhang; Siying Zhou; Yunjie He; Heda Zhang; Fei Deng; Hanzi Xu; Shanliang Zhong; Li Fu; Jinhai Tang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

Review 6.  [Advances in serum biomarkers for early diagnosis of gastric cancer].

Authors:  Yunzhu Zhang; Chunpeng Zhu; Xinliang Lu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25

Review 7.  The role of circRNAs in cancers.

Authors:  Ling-Ping Zhu; Yun-Jie He; Jun-Chen Hou; Xiu Chen; Si-Ying Zhou; Su-Jin Yang; Jian Li; He-Da Zhang; Jia-Hua Hu; Shan-Liang Zhong; Jian-Hua Zhao; Jin-Hai Tang
Journal:  Biosci Rep       Date:  2017-10-24       Impact factor: 3.840

Review 8.  The Emerging Role of Circ-SHPRH in Cancer.

Authors:  Xinyue Ju; Yan Tang; Rongfeng Qu; Shuhong Hao
Journal:  Onco Targets Ther       Date:  2021-07-13       Impact factor: 4.147

Review 9.  Circular RNAs: clinical relevance in cancer.

Authors:  Zhijie Xu; Yuanliang Yan; Shuangshuang Zeng; Shuang Dai; Xi Chen; Jie Wei; Zhicheng Gong
Journal:  Oncotarget       Date:  2017-12-01

Review 10.  Circular RNAs: Biogenesis, Function, and a Role as Possible Cancer Biomarkers.

Authors:  Luka Bolha; Metka Ravnik-Glavač; Damjan Glavač
Journal:  Int J Genomics       Date:  2017-12-04       Impact factor: 2.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.